Published in Mol Pharmacol on August 22, 2007
Nitric oxide-induced conformational changes in soluble guanylate cyclase. Structure (2014) 1.55
PAS-mediated dimerization of soluble guanylyl cyclase revealed by signal transduction histidine kinase domain crystal structure. J Biol Chem (2007) 1.37
Crystal structure of the signaling helix coiled-coil domain of the beta1 subunit of the soluble guanylyl cyclase. BMC Struct Biol (2010) 1.07
Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol (2009) 1.06
Higher-order interactions bridge the nitric oxide receptor and catalytic domains of soluble guanylate cyclase. Proc Natl Acad Sci U S A (2013) 1.05
Alpha1 soluble guanylyl cyclase (sGC) splice forms as potential regulators of human sGC activity. J Biol Chem (2008) 0.97
Fluorescent fusion proteins of soluble guanylyl cyclase indicate proximity of the heme nitric oxide domain and catalytic domain. PLoS One (2010) 0.95
Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase. Br J Pharmacol (2009) 0.87
Single-particle EM reveals the higher-order domain architecture of soluble guanylate cyclase. Proc Natl Acad Sci U S A (2014) 0.85
The amino-terminus of nitric oxide sensitive guanylyl cyclase α₁ does not affect dimerization but influences subcellular localization. PLoS One (2011) 0.85
Interfacial residues promote an optimal alignment of the catalytic center in human soluble guanylate cyclase: heterodimerization is required but not sufficient for activity. Biochemistry (2014) 0.83
Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells. PLoS One (2011) 0.83
A peptide against soluble guanylyl cyclase α1: a new approach to treating prostate cancer. PLoS One (2013) 0.83
Heat Shock Protein 90 Associates with the Per-Arnt-Sim Domain of Heme-free Soluble Guanylate Cyclase: IMplications for Enzyme Maturation. J Biol Chem (2015) 0.81
Sulfhydryl-dependent dimerization of soluble guanylyl cyclase modulates the relaxation of porcine pulmonary arteries to nitric oxide. Pflugers Arch (2012) 0.76
The Influence of Nitric Oxide on Soluble Guanylate Cyclase Regulation by Nucleotides: ROLE OF THE PSEUDOSYMMETRIC SITE. J Biol Chem (2015) 0.76
Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives. Antioxid Redox Signal (2016) 0.75
Probing the Molecular Mechanism of Human Soluble Guanylate Cyclase Activation by NO in vitro and in vivo. Sci Rep (2017) 0.75
Peptide B targets soluble guanylyl cyclase α1 and kills prostate cancer cells. PLoS One (2017) 0.75
Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension (2007) 5.80
Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem (2004) 3.37
Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res (2007) 3.28
Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation (2005) 3.12
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol (2010) 2.72
Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med (2008) 2.68
The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (2006) 2.55
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest (2006) 2.52
Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med (2010) 2.12
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol (2002) 1.90
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation (2013) 1.78
NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res (2005) 1.65
Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem (2003) 1.61
NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther (2008) 1.58
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation (2006) 1.55
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension (2006) 1.50
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med (2014) 1.48
Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol (2007) 1.47
NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol (2009) 1.45
The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci (2012) 1.44
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem (2009) 1.36
Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem (2010) 1.34
Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med (2004) 1.31
Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun (2006) 1.30
The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med (2004) 1.30
Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res (2009) 1.29
Hemodynamic and biochemical adaptations to vascular smooth muscle overexpression of p22phox in mice. Am J Physiol Heart Circ Physiol (2004) 1.26
Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. Nat Commun (2012) 1.25
Synaptic localization of nitric oxide synthase and soluble guanylyl cyclase in the hippocampus. J Neurosci (2002) 1.24
Good stress, bad stress--the delicate balance in the vasculature. Dtsch Arztebl Int (2009) 1.23
Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension (2010) 1.23
Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat Cell Biol (2002) 1.21
Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun (2003) 1.18
The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl (2013) 1.18
The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease. J Nutr Biochem (2008) 1.16
Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol (2003) 1.16
Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab (2012) 1.15
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens (2010) 1.15
Effect of gender on NADPH-oxidase activity, expression, and function in the cerebral circulation: role of estrogen. Stroke (2007) 1.13
Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. Eur J Pharmacol (2005) 1.11
Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun (2006) 1.10
Translating the oxidative stress hypothesis into the clinic: NOX versus NOS. J Mol Med (Berl) (2009) 1.05
Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung (2008) 1.05
Nucleotidyl cyclase activity of soluble guanylyl cyclase α1β1. Biochemistry (2011) 1.05
Aspirin reduces endothelial cell senescence. Biochem Biophys Res Commun (2005) 1.04
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One (2011) 1.04
BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur Heart J (2009) 1.04
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am J Physiol Heart Circ Physiol (2011) 1.04
Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. Antioxid Redox Signal (2012) 1.03
Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci U S A (2004) 1.03
Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. Am J Physiol Heart Circ Physiol (2011) 1.02
Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun (2006) 1.01
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One (2012) 1.00
Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Lett (2006) 1.00
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol (2003) 0.99
Distribution of soluble guanylyl cyclase in the rat brain. J Comp Neurol (2004) 0.99
There's NO binding like NOS binding: protein-protein interactions in NO/cGMP signaling. Proc Natl Acad Sci U S A (2002) 0.98
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc (2013) 0.98
The 'A's and 'O's of NADPH oxidase regulation: a commentary on "Subcellular localization and function of alternatively spliced Noxo1 isoforms". Free Radic Biol Med (2006) 0.98
A constitutive NADPH oxidase-like system containing gp91phox homologs in human keratinocytes. J Invest Dermatol (2004) 0.98
Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol (2004) 0.98
A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther (2010) 0.98
Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation (2002) 0.97
Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs (2011) 0.96
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med (2007) 0.96
Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg (2010) 0.96
Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2011) 0.95
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol (2006) 0.95
Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol (2012) 0.95
cGMP in the vasculature. Handb Exp Pharmacol (2009) 0.94
Pharmacological profile of a novel H(2)S-releasing aspirin. Free Radic Biol Med (2008) 0.94
Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases. J Med Chem (2005) 0.93
NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid Redox Signal (2013) 0.93
Antioxidant action of L-alanine: heme oxygenase-1 and ferritin as possible mediators. Biochem Biophys Res Commun (2004) 0.92
Gastroprotection by vitamin C--a heme oxygenase-1-dependent mechanism? Biochem Biophys Res Commun (2003) 0.92
Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. PLoS One (2011) 0.91
Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. Mol Pharmacol (2002) 0.91
L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int (2002) 0.90
Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J Am Soc Nephrol (2006) 0.90
Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res (2009) 0.90
Heat shock protein 90 regulates stabilization rather than activation of soluble guanylate cyclase. FEBS Lett (2007) 0.90
L-Arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats. Kidney Int (2003) 0.90
Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci (2010) 0.89
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation (2003) 0.89